The Pharma Data

MAY 6, 2021

Under the MoU, the companies and the IOC will coordinate with National Olympic Committees (NOCs) around the world to understand and work to help address the local need for vaccine doses for national delegations’ participation in the Games. This press release features multimedia. View the full release here: [link].

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

DECEMBER 28, 2020

Centers for Disease Control and Prevention said Saturday. EU Kicks Off COVID-19 Vaccine Campaign. Starting with health care workers and the elderly, the European Union has begun a massive program to vaccinate millions against COVID-19, according to the Associated Press. Travelers Travelers flying to the U.S. Weeks after the U.S.,

Vaccine 52

Vaccine Virus Nurses Science 52

The Pharma Data

DECEMBER 21, 2020

military scientists to determine if it might be resistant to vaccines. The deal also includes more than $30 billion to acquire and distribute coronavirus vaccines and $27 billion for testing and state health care programs. Higher flu vaccination rates are one reason why flu cases are way down in the United States, experts say.

Vaccine 52

Vaccine Packaging Laboratories Virus 52

The Pharma Data

NOVEMBER 9, 2020

DAEGU, KOREA, November 09, 2020 /24-7PressRelease/ — South Korean religious group Shincheonji Church of Jesus has announced their third convalescent plasma donation drive to take place for 3 weeks starting November 16th at an Indoor Athletics Center in Daegu. Approximately 4,000 members of the group are expected to participate.

Treatment 145

Treatment Vaccine Disease 145

The Pharma Data

JANUARY 21, 2021

Percent of Kindergarteners Not Up to Date With MMR in 2019-2020. percent of kindergarteners were not up to date with measles, mumps, and rubella (MMR) vaccination and did not have an exemption in the 2019 to 2020 school year, according to research published in the Jan. The researchers found that vaccination coverage was 94.9,

Vaccine 52

Vaccine Disease Research 52

The Pharma Data

APRIL 14, 2021

The product’s early Marek’s disease onset of immunity from five days of age provides full protection of broilers, layers and breeders against the most virulent Marek’s disease virus strains. Its purpose is to provide poultry producers with cutting-edge technology in terms of Marek’s disease protection.

Vaccine 52

Vaccine Disease Virus Engineering 52

The Pharma Data

DECEMBER 31, 2020

Monthly News Roundup – December 2020. Moderna and Pfizer’s COVID-19 Vaccines Roll Out in Early Phase. Food and Drug Administration (FDA) issued Emergency Use Authorization for two COVID-19 vaccines: Pfizer-BioNTech’s BNT162b2 and Moderna’s mRNA-1273. The partial piece of the spike protein cannot cause COVID-19 disease.

FDA Approval 52

FDA Approval Vaccine FDA Treatment 52

The Pharma Data

DECEMBER 8, 2020

AstraZeneca (AZ) and the University of Oxford have presented new data from a “pooled analysis” of phase 3 trials evaluating COVID-19 vaccine AZD1222 at two different dose regimens, demonstrating an average efficacy of 70.4 The University of Oxford claims no vaccinated participants were hospitalized or suffered serious forms of the disease.

Vaccine 52

Vaccine Trials Hospitals Disease 52

The Pharma Data

DECEMBER 14, 2020

14, 2020 — The Pfizer-BioNTech COVID-19 vaccine has received the first emergency use authorization (EUA) for a COVID-19 vaccine in the United States. Centers for Disease Control and Prevention Director Robert R. The vaccine is administered in two doses three weeks apart. MONDAY, Dec. Redfield, M.D.,

Vaccine 52

Vaccine Nurses FDA Virus 52

The Pharma Data

DECEMBER 17, 2020

Advisory Committee Votes to Recommend EUA for Moderna Vaccine. 17, 2020 — The Moderna COVID-19 vaccine received recommendation from a U.S. Food and Drug Administration advisory committee on Thursday, clearing the way for it to become the second COVID-19 vaccine to be granted emergency use authorization.

Vaccine 52

Vaccine Clinical Trials Government FDA 52

The Pharma Data

DECEMBER 8, 2020

8, 2020 — AstraZeneca’s COVID-19 vaccine is safe and effective, new data from late-stage trials shows. Overall, the vaccine protected against symptomatic disease in 70% of cases, according to a team led by researchers from Oxford University in England. TUESDAY, Dec. 8 in The Lancet.

Vaccine 52

Vaccine Trials Immune Response RNA 52

The Pharma Data

FEBRUARY 8, 2021

Q4 2020 sales growth (2) of 4.2% Vaccines up 14.6%, driven by record demand for differentiated influenza vaccines and continued growth of PPH. Full-year 2020 performance. to €36,041 million, driven by Dupixent ® (€3,534 million, up 73,9%) and Vaccines. and business EPS growth of 9.8% to €982 million).

Vaccine 52

Vaccine Production FDA Therapies 52

The Pharma Data

DECEMBER 11, 2020

11, 2020 — More than 15 million Americans have been infected by the COVID-19 virus, and many may be questioning whether they need to receive one of the two coronavirus vaccines now on the verge of approval from U.S. William Schaffner, a professor of infectious diseases at Vanderbilt University Medical Center in Nashville, Tenn.

Vaccine 52

Vaccine Immune Response Virus Trials 52

The Pharma Data

DECEMBER 22, 2020

22, 2020 — In very rare cases, some people have had severe allergic reactions after receiving the new COVID-19 vaccines, leading the American College of Allergy , Asthma, and Immunology (ACAAI) to issue updated guidance for Americans with allergies. © 2020 HealthDay. TUESDAY, Dec.

Vaccine 52

Vaccine Immune Response Treatment Disease 52

The Pharma Data

JUNE 29, 2021

Sanofi will invest approximately €400 million annually in a first-of-its kind vaccines mRNA Center of Excellence. “During the COVID-19 pandemic, mRNA technologies demonstrated potential to deliver new vaccines faster than ever before. . ” said Thomas Triomphe, Executive Vice President, Global Head of Sanofi Pasteur.

Vaccine 52

Vaccine Disease International Treatment 52

The Pharma Data

DECEMBER 19, 2020

20, 2020 02:44 UTC. Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the U.S. 11 ACIP members voted in favor of the vaccine and 0 members voted against. We look forward to vaccinations of this important population starting this week.”. CAMBRIDGE, Mass.–(

Vaccine 52

Vaccine Long-Term Care Facilities FDA Licensing 52

The Pharma Data

JUNE 26, 2021

Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine. The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. JUNE 22 , 2021. We look forward to sharing initial results by year-end. ”. “

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

DrugBaron

NOVEMBER 9, 2020

The first death unequivocally caused by COVID was reported to the world on January 11 th 2020 – that’s just 303 days ago (even if it feels like a lifetime away). Indeed, China has already licensed a vaccine, albeit without the data that would typically be required to support such an approval. But that cannot be the whole answer.

Vaccine 100

Vaccine Pharmaceutical Companies Government Pharmaceuticals 100

The Pharma Data

DECEMBER 21, 2020

21, 2020 — A second COVID-19 vaccine is poised to be administered in the coming weeks after the U.S. Food and Drug Administration granted emergency use authorization (EUA) to the Moderna COVID-19 vaccine on Friday. The EUA allows for the vaccine to be administered to adults 18 years and older in two doses one month apart.

Vaccine 52

Vaccine FDA Hospitals Disease 52

The Pharma Data

JANUARY 6, 2021

(Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Commission has granted a conditional marketing authorization (CMA) for COVID-19 Vaccine Moderna, allowing vaccination programs using the Moderna vaccine to be rolled out across the European Union.

Vaccine 52

Vaccine FDA RNA Clinical Trials 52

The Pharma Data

JULY 8, 2021

People who receive mRNA COVID-19 vaccines are up to 91 percent less likely to develop the disease than those who are unvaccinated, according to a new nationwide study of eight sites, including Salt Lake City. Those who unfortunately got COVID-19 despite being vaccinated were still better off than those who didn’t.”

Vaccine 52

Vaccine Virus Nurses Hospitals 52

The Pharma Data

JANUARY 7, 2021

Anaphylaxis Cases/Million Doses of Pfizer-BioNTech COVID-19 Vaccine Reported. 23, 2020, researchers determined there were 21 cases of anaphylaxis (11.1 per million doses administered) after receipt of the first dose of the Pfizer-BioNTech COVID-19 vaccine in the United States, according to research published in the Jan.

Vaccine 52

Vaccine Research Disease Drugs 52

The Pharma Data

JUNE 25, 2021

In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria. About CVnCoV. About CVnCoV.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

JULY 15, 2021

FreVAX is an innovative intramuscular needle free vaccine injection device for pigs around weaning until the end of nursery. FreVAX intramuscular needle free device has been available since December 2020 to swine producers globally. We develop solutions and provide services to protect animals from disease and pain.

Vaccine 52

Vaccine Compliance Disease 52

The Pharma Data

JUNE 24, 2021

The primary objective in the trial is to describe safety when both vaccines are co-administered, with follow up six months after vaccination. Secondary objectives are to describe immune responses produced by each of the vaccines. Secondary objectives are to describe immune responses produced by each of the vaccines.

Vaccine 52

Vaccine Immune Response FDA Licensing 52

The Pharma Data

DECEMBER 30, 2020

30 December 2020 — AstraZeneca’s COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New Year. This is the first authorisation for this vaccine.

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

DECEMBER 12, 2020

12, 2020 – The U.S. Food and Drug Administration approved Pfizer’s coronavirus vaccine for emergency use on Friday, clearing the way for the launch of a national campaign to inoculate enough Americans to stem the spread of COVID-19. ” Who is first in line to be vaccinated? SATURDAY, Dec.

Vaccine 52

Vaccine FDA Approval FDA Nurses 52

The Pharma Data

MARCH 11, 2021

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced real-world evidence demonstrating dramatically lower incidence rates of COVID-19 disease in individuals fully vaccinated with the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2), underscoring the observed substantial public health impact of Israel’s nationwide immunization program.

Vaccine 52

Vaccine Clinical Trials Hospitals Licensing 52

The Pharma Data

MARCH 11, 2021

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2, the virus that causes COVID-19.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

FEBRUARY 4, 2021

Q4 2020 sales growth (2) of 4.2% Vaccines up 14.6%, driven by record demand for differentiated influenza vaccines and continued growth of PPH. Full-year 2020 performance. to €36,041 million, driven by Dupixent ® (€3,534 million, up 73,9%) and Vaccines. and business EPS growth of 9.8% to €982 million).

Vaccine 52

Vaccine Production FDA Therapies 52

The Pharma Data

MARCH 24, 2021

billion EUR in 2020 (18.9% Boehringer Ingelheim stepped up its investments in R&D significantly in 2020 in pursuit of innovative medicines and therapies for diseases for which no satisfactory treatments are available. Our achievements in 2020 are the result of their effort.”. Overall R&D investment up 7% to 3.7

Therapies 52

Therapies Disease Vaccine Small Molecule 52

The Pharma Data

JANUARY 25, 2021

In a surprise move, Merck announced that it is giving up on its two coronavirus vaccine candidates after seeing a subpar immune response and shifting its focus to a pair of investigational coronavirus treatments. 24, 2020 ). 28, 2020 ). The drugmaker’s decision coincides with a tightening of vaccine supplies in the U.S.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

The Pharma Data

DECEMBER 14, 2020

14, 2020 (Healthday News) — The first shipments of nearly 3 million doses of the Pfizer coronavirus vaccine were on their way to hospitals in all 50 U.S. Because the vaccines can cause side effects including fevers and aches, hospitals have said they will stagger vaccinations among their workers. MONDAY, Dec.

Vaccine 52

Vaccine Nurses Assisted Living Hospitals 52

The Pharma Data

DECEMBER 30, 2020

The year 2020 will certainly go down in history as the year of COVID-19. Gilead Sciences Makes Multiple Bets : When Gilead Sciences wasn’t working on remdesivir in COVID-19, the company seemed to be constantly flexing its M&A muscle over the course of 2020. It began in May with the $4.9 But the U.K.-based

Science 52

Science Disease Pharmaceuticals Treatment 52

The Pharma Data

DECEMBER 11, 2020

11, 2020 – The U.S. Food and Drug Administration is expected to approve emergency use of Pfizer’s coronavirus vaccine as early as Saturday after its advisory panel cleared the way for the start of a national campaign to inoculate Americans and stem the spread of COVID-19. Centers for Disease Control and Prevention.

Vaccine 52

Vaccine FDA Hospitals Doctors 52

The Pharma Data

JANUARY 11, 2021

Moderna is following up on the success of its messenger RNA-based COVID-19 vaccine with plans to develop inoculations for numerous other infectious diseases, the company said Monday. 18, 2020 ). based company has been in business for 10 years, but the COVID-19 vaccine was its first approved product.

Vaccine 52

Vaccine Clinical Trials Virus RNA 52

The Pharma Data

OCTOBER 7, 2021

COVID-19 vaccines are highly effective in preventing symptomatic illness among health care workers in real-world settings. For those who received the two-dose regimen of the Moderna vaccine, the risk was reduced by 96%. The vaccines’ effectiveness was, however, lower in immunocompromised people.

Vaccine 52

Vaccine Disease Research 52